Our insurer partners are the licensed product issuers in each market. Beacon provides the complete go-to-market infrastructure; our partners provide the regulatory licence and customer relationships.

Pharmaceutical integration is what separates Beacon from every other broker. Our pharma partnerships ensure that when a claim is approved, the treatment is actually accessible.

Beacon’s structural architecture is anchored by a highly sophisticated, institutional shareholder and affiliate base that injects both cross-border capital and significant market scale into our operations.

Strategic Regional Affiliation: Through our primary corporate affiliation with KunPeng Insurance Brokers China, Beacon commands immediate access to a deep regional network that generated RMB 14 billion in premium in 2024, bridging robust North Asian reinsurance capacity directly into Southeast Asian growth corridors.

Institutional Equity Backing: Our capitalization is reinforced by strategic corporate shareholders, including Neologics Bioscience Holdings Limited, establishing an explicit validation layer from advanced scientific and technology sectors. This unique equity backing cross-validates our core specialty risk-pooling frameworks, providing our insurance partners and incoming investment groups with an unrivaled foundation of trust, scalability, and long-term asset defensibility.